Brassinosteroids cause cell cycle arrest and apoptosis of human breast cancer cells.

Brassinosteroids (BRs) are plant hormones that appear to be ubiquitous in both lower and higher plants. Recently, we published the first evidence that some natural BRs induce cell growth inhibitory responses in several human cancer cell lines without affecting normal non-tumor cell growth (BJ fibroblasts). The aim of the study presented here was to examine the mechanism of the antiproliferative activity of the natural BRs 28-homocastasterone (28-homoCS) and 24-epibrassinolide (24-epiBL) in human hormone-sensitive and -insensitive (MCF-7 and MDA-MB-468, respectively) breast cancer cell lines. The effects of 6, 12 and 24h treatments with 28-homoCS and 24-epiBL on cancer cells were surveyed using flow cytometry, Western blotting, TUNEL assays and immunofluorescence analyses. The studied BRs inhibited cell growth and induced blocks in the G(1) cell cycle phase. ER-α immunoreactivity was uniformly present in the nuclei of control MCF-7 cells, while cytoplasmic speckles of ER-α immunofluorescence appeared in BR-treated cells (IC(50), 24h). ER-β was relocated to the nuclei following 28-homoCS treatment and found predominantly at the periphery of the nuclei in 24-epiBL-treated cells after 24h of treatment. These changes were also accompanied by down-regulation of the ERs following BR treatment. In addition, BR application to breast cancer cells resulted in G(1) phase arrest. Furthermore, TUNEL staining and double staining with propidium iodide and acridine orange demonstrated the BR-mediated induction of apoptosis in both cell lines, although changes in the expression of apoptosis-related proteins were modulated differently by the BRs in each cell line. The studied BRs seem to exert potent growth inhibitory effects via interactions with the cell cycle machinery, and they could be highly valuable leads for agents for managing breast cancer.

[1]  R. Lotan,et al.  Examining the role of mitochondrial respiration in vanilloid-induced apoptosis. , 2002, Journal of the National Cancer Institute.

[2]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[3]  P. Legrand,et al.  In vitro and in vivo biologic evaluation of long‐circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668 , 2003, International journal of cancer.

[4]  V. Craig Jordan,et al.  International Union of Pharmacology. LXIV. Estrogen Receptors , 2006, Pharmacological Reviews.

[5]  J. Polman,et al.  ER beta: identification and characterization of a novel human estrogen receptor. , 1996, FEBS letters.

[6]  A. Giordano,et al.  The regulation of ER-alpha transcription by pRb2/p130 in breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  G. Mundy,et al.  Direct resorption of bone by human breast cancer cells in vitro , 1978, Nature.

[8]  R. Dickson,et al.  Of Mice and Myc: c-Myc and Mammary Tumorigenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[9]  Michele D. Sobolewski,et al.  Sulforaphane induces cell type–specific apoptosis in human breast cancer cell lines , 2007, Molecular Cancer Therapeutics.

[10]  A. Chinnaiyan,et al.  Molecular Ordering of the Cell Death Pathway , 1996, The Journal of Biological Chemistry.

[11]  Robert L Sutherland,et al.  Cell cycle control in breast cancer cells , 2006, Journal of cellular biochemistry.

[12]  N. Magné,et al.  Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines , 2005, Breast Cancer Research.

[13]  A. Brodie,et al.  Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. , 2003, Cancer research.

[14]  J. Carroll,et al.  p27Kip1 Induces Quiescence and Growth Factor Insensitivity in Tamoxifen-treated Breast Cancer Cells , 2003 .

[15]  E. Solary,et al.  Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs* , 1999, The Journal of Biological Chemistry.

[16]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[17]  Fritz F. Parl,et al.  Estrogens, Estrogen Receptor, and Breast Cancer , 2000 .

[18]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[19]  K. Coser,et al.  The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Mester,et al.  Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Miroslav Strnad,et al.  Anticancer and antiproliferative activity of natural brassinosteroids. , 2008, Phytochemistry.

[22]  J. Carroll,et al.  Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. , 2003, Endocrine-related cancer.

[23]  Chris Albanese,et al.  Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. , 2002, The Journal of biological chemistry.

[24]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[25]  A. Lenferink,et al.  Cyclin-Dependent Kinase Inhibitor P27Kip1 Is Required for Mouse Mammary Gland Morphogenesis and Function , 2001, The Journal of cell biology.

[26]  A. Giordano,et al.  The regulation of ER-α transcription by pRb2/p130 in breast cancer , 2005 .

[27]  E. Woltering,et al.  Many ways to exit? Cell death categories in plants. , 2005, Trends in plant science.

[28]  Fengzhi Li,et al.  Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. , 2007, Cancer research.

[29]  P. Ascenzi,et al.  Structure–function relationship of estrogen receptor α and β: Impact on human health , 2006 .

[30]  William Rostène,et al.  Antiestrogens are pro‐apoptotic in normal human breast epithelial cells , 2003, International journal of cancer.

[31]  K C Nicolaou,et al.  Behind enemy lines. , 2001, Scientific American.

[32]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[33]  H. Mo,et al.  Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention , 2004, Experimental biology and medicine.

[34]  V. Jordan SERMs: meeting the promise of multifunctional medicines. , 2007, Journal of the National Cancer Institute.

[35]  L. Attardi,et al.  The role of apoptosis in cancer development and treatment response , 2005, Nature Reviews Cancer.

[36]  Rachel Schiff,et al.  Estrogen-receptor biology: continuing progress and therapeutic implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  E. Appella,et al.  Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. , 2006, Cancer cell.

[38]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[39]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[40]  C. Buckley Behind enemy lines. , 1996, Tobacco control.

[41]  C. Tashima Estrogen receptor assay. , 1977, JAMA.

[42]  S. Clouse Brassinosteroid Signaling: Novel Downstream Components Emerge , 2002, Current Biology.

[43]  F. Bray,et al.  The changing global patterns of female breast cancer incidence and mortality , 2004, Breast Cancer Research.

[44]  A. Giordano,et al.  Epigenetic information and estrogen receptor alpha expression in breast cancer. , 2006, The oncologist.

[45]  A. Tretyn,et al.  The chemical characteristic and distribution of brassinosteroids in plants. , 2003, Phytochemistry.

[46]  Alan G. Porter,et al.  Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis* , 1998, The Journal of Biological Chemistry.

[47]  Suzanne A. W. Fuqua,et al.  Estrogen receptor and breast cancer , 2001 .

[48]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[49]  Massimo Loda,et al.  Role of p27 in Prostate Carcinogenesis , 2004, Cancer and Metastasis Reviews.

[50]  J. Carroll,et al.  p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. , 2003, Cancer research.

[51]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[52]  M. Parmar,et al.  Clinical trials in ovarian carcinoma: study methodology. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  J. Carroll,et al.  A Low Abundance Pool of Nascent p21WAF1/Cip1 Is Targeted by Estrogen to Activate Cyclin E·Cdk2* , 2001, The Journal of Biological Chemistry.

[54]  R. Yu,et al.  Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. , 2000, Cancer research.

[55]  Chin-Yo Lin,et al.  Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. , 2006, Cancer research.

[56]  N. Boulle,et al.  Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. , 2007, Cancer research.

[57]  Sander van den Heuvel,et al.  Conserved functions of the pRB and E2F families , 2008, Nature Reviews Molecular Cell Biology.

[58]  David J Newman,et al.  Advanced preclinical and clinical trials of natural products and related compounds from marine sources. , 2004, Current medicinal chemistry.

[59]  Chris Albanese,et al.  Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression* , 2002, The Journal of Biological Chemistry.

[60]  William Rostène,et al.  Hormonal regulation of apoptosis in breast cells and tissues , 2000, Steroids.

[61]  A. deFazio,et al.  Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. , 1995, Molecular endocrinology.

[62]  N. Saijo,et al.  Mechanism of action of aragusterol a (YTA0040), a potent anti‐tumor marine steroid targeting the G1 phase of the cell cycle , 2000, International journal of cancer.

[63]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.